# Cabazitaxel in Platinum Refractory Ovarian Cancer

> **NCT01747239** · PHASE2 · TERMINATED · sponsor: **Vejle Hospital** · enrollment: 4 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT01747239
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Too low inclusion rate. Only 4 patients included over 16 months
- **Last updated:** 2014-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01747239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01747239, "Cabazitaxel in Platinum Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01747239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*